Halozyme Therapeutics, Inc. (HALO) Insider Trading Activity

NASDAQ$101.31-0.37 (-0.36%)
Market Cap
$11.59B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
564 of 843
Rank in Industry
329 of 489

HALO Insider Trading Activity

HALO Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
0
Sells
$47,270,139
40
100

Related Transactions

Krishnan Maheshdirector
0
$0
1
$547,800
$-547,800
Connaughton Bernadettedirector
0
$0
6
$702,406
$-702,406
Caudill CortneySVP, CHIEF OPERATING OFFICER
0
$0
2
$1.96M
$-1.96M
Posard Matthew L.director
0
$0
2
$2.61M
$-2.61M
Torley HelenPRESIDENT AND CEO
0
$0
30
$42.83M
$-42.83M

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.

Insider Activity of Halozyme Therapeutics, Inc.

Over the last 12 months, insiders at Halozyme Therapeutics, Inc. have bought $0 and sold $47.27M worth of Halozyme Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Halozyme Therapeutics, Inc. have bought $0 and sold $28.6M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 52,629 shares for transaction amount of $748,697 was made by Kelley Kenneth J (director) on 2020‑03‑19.

List of Insider Buy and Sell Transactions, Halozyme Therapeutics, Inc.

2026-10-08SaleTorley HelenPRESIDENT AND CEO
20,000
0.0168%
$109.40
$2.19M
+12.59%
2026-10-07SaleTorley HelenPRESIDENT AND CEO
20,000
0.017%
$111.55
$2.23M
+10.98%
2026-10-06SaleTorley HelenPRESIDENT AND CEO
20,000
0.0168%
$109.58
$2.19M
+11.86%
2026-10-01SalePosard Matthew L.director
5,230
0.0045%
$108.54
$567,661
+13.93%
2026-09-16SalePosard Matthew L.director
18,996
0.0159%
$107.74
$2.05M
+4.57%
2026-09-11SaleTorley HelenPRESIDENT AND CEO
20,000
0.0169%
$107.24
$2.14M
+4.90%
2026-09-10SaleTorley HelenPRESIDENT AND CEO
20,000
0.0169%
$107.17
$2.14M
+5.09%
2026-09-09SaleTorley HelenPRESIDENT AND CEO
20,000
0.0169%
$107.43
$2.15M
+4.70%
2026-08-19SaleTorley HelenPRESIDENT AND CEO
16,800
0.0141%
$106.85
$1.8M
+2.58%
2026-08-19SaleTorley HelenPRESIDENT AND CEO
20,000
0.0168%
$107.00
$2.14M
+2.58%
2026-08-18SaleTorley HelenPRESIDENT AND CEO
20,000
0.0167%
$104.18
$2.08M
+5.15%
2026-08-17SaleTorley HelenPRESIDENT AND CEO
20,000
0.017%
$102.60
$2.05M
+6.98%
2026-08-10SaleConnaughton Bernadettedirector
1,626
0.0014%
$102.80
$167,153
+6.98%
2026-07-08SaleTorley HelenPRESIDENT AND CEO
1,923
0.0016%
$79.77
$153,391
+34.03%
2026-07-01SaleConnaughton Bernadettedirector
1,625
0.0014%
$76.71
$124,651
+39.45%
2026-06-29SaleKrishnan Maheshdirector
7,304
0.006%
$75.00
$547,800
+38.90%
2026-06-03SaleTorley HelenPRESIDENT AND CEO
3,900
0.0032%
$68.09
$265,532
+50.56%
2026-06-03SaleTorley HelenPRESIDENT AND CEO
10,000
0.0088%
$69.07
$690,653
+50.56%
2026-06-02SaleTorley HelenPRESIDENT AND CEO
20,000
0.0169%
$66.39
$1.33M
+58.25%
2026-06-01SaleTorley HelenPRESIDENT AND CEO
20,000
0.0167%
$67.58
$1.35M
+53.01%
Total: 370
*Gray background shows transactions not older than one year

Insider Historical Profitability

72.81%
Torley HelenPRESIDENT AND CEO
767780
0.6734%
$78.07M191
+68.25%
Posard Matthew L.director
53609
0.047%
$5.45M010
Connaughton Bernadettedirector
40418
0.0355%
$4.11M09
Krishnan Maheshdirector
14462
0.0127%
$1.47M01
Caudill CortneySVP, CHIEF OPERATING OFFICER
7055
0.0062%
$717,352.4003
Frost Gregory IanCEO, President
3555331
3.1184%
$361.51M416
+20.07%
KIRK RANDAL J10 percent owner
1897610
1.6644%
$192.95M5618
+103.3%
Lim Jonathan EPresident, CEO
680000
0.5964%
$69.14M18
+18.01%
RAMSAY DAVID AVP and Chief Financial Officer
323492
0.2837%
$32.89M73
+24.44%
FALBERG KATHRYN Edirector
280000
0.2456%
$28.47M30
+46.53%
Engler Robertdirector
273176
0.2396%
$27.78M53
+18.07%
MATSUI CONNIEdirector
181983
0.1596%
$18.5M02
PATTON JOHN STUARTdirector
179876
0.1578%
$18.29M022
Kelley Kenneth Jdirector
179833
0.1577%
$18.29M322
+50.56%
LaBarre Michael J.SVP, CHIEF TECHNICAL OFFICER
173756
0.1524%
$17.67M048
Yocum Richard CVP Clinical Development
65975
0.0579%
$6.71M01
BIZZARI JEAN-PIERREdirector
52544
0.0461%
$5.34M01
Chondros DimitriosSVP, Chief Medical Officer
38584
0.0338%
$3.92M02
Henderson Jeffrey Williamdirector
28611
0.0251%
$2.91M08
Shaffer James PVP & Chief Commercial Officer
26300
0.0231%
$2.67M10
+34.45%
LaBrosse NicoleSVP, CHIEF FINANCIAL OFFICER
22079
0.0194%
$2.24M08
Daly James Mdirector
20503
0.018%
$2.08M04
Thornton Steven Tdirector
15000
0.0132%
$1.53M03
Shepard H. MichaelVP, Chief Scientific Officer
13198
0.0116%
$1.34M01
LITTLE ROBERT JVP, Chief Commercial Officer
13000
0.0114%
$1.32M20
<0.0001%
Stelzer LaurieChief Financial Officer
10000
0.0088%
$1.02M10
<0.0001%
GUSTAFSON KURT AVice President and CFO
8000
0.007%
$813,440.0010
Kennard Don AVice President, Regulatory Aff
3000
0.0026%
$305,040.0010
+31.79%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$961,890,236
276
22.46%
$24.92B
$273,531,368
93
38.24%
$10.06B
$2,765,836
72
20.00%
$11.3B
Halozyme Therapeutics, Inc.
(HALO)
$108,876,545
67
72.81%
$11.59B
$11,991,408
51
18.36%
$26.49B
$323,530,732
48
29.90%
$21.41B
$98,300,471
40
0.27%
$15.93B
$19,233,721
36
70.14%
$17.77B
$13,655,378
35
17.13%
$25.37B
$650,670,576
22
96.65%
$13.27B
$415,090,639
19
-14.04%
$15.49B
$118,094,211
15
38.32%
$11.51B
$9,976,473
12
29.52%
$9.68B
$35,908,794
10
126.31%
$8.8B
$11,898,979
10
54.58%
$9.15B
$948,235
8
15.54%
$11.44B
$2,246,813
6
70.15%
$9.94B
$40,326,230
5
44.68%
$30.32B
$41,376,000
4
-12.07%
$10.8B

HALO Institutional Investors: Active Positions

Increased Positions332+48.12%18M+14.8%
Decreased Positions309-44.78%15M-12.14%
New Positions106New5MNew
Sold Out Positions79Sold Out4MSold Out
Total Postitions713+3.33%124M+2.66%

HALO Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Blackrock, Inc.$904,201.0010.9%12.86M-339,833-2.57%2025-09-30
Vanguard Group Inc$817,690.009.86%11.63M-615,816-5.03%2025-09-30
State Street Corp$352,900.004.25%5.02M-915,838-15.43%2025-09-30
Arrowstreet Capital, Limited Partnership$231,367.002.79%3.29M+749,484+29.49%2025-09-30
Invesco Ltd.$228,210.002.75%3.25M-220,119-6.35%2025-09-30
Ubs Group Ag$207,116.002.5%2.95M+1M+93.24%2025-09-30
Snyder Capital Management L P$192,217.002.32%2.73M-663,853-19.54%2025-09-30
D. E. Shaw & Co., Inc.$186,348.002.25%2.65M+2M+160.15%2025-09-30
Geode Capital Management, Llc$170,943.002.06%2.43M-1,230-0.05%2025-09-30
Dimensional Fund Advisors Lp$146,134.001.76%2.08M+63,699+3.16%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.